5-Fluorouracil in Facial Plastic Surgery: Indications, Efficacy, and Safety - A Systematic Review and Narrative Synthesis

被引:0
作者
Bogari, Ahmad [1 ]
Jomah, Mohammed [1 ]
Alshehri, Naif [2 ]
Alrabiah, Hamad F. [2 ]
Binghaith, Abdullah [2 ]
AlOsaimi, Khalid [2 ]
Aldhwaihy, Lulu [3 ]
Baghazal, Alaa [4 ]
Bogari, Hassan [5 ]
机构
[1] King Saud Univ, Coll Med, Dept Otolaryngol Head & Neck Surg, Facial Plast Surg Unit, Riyadh, Riyadh, Saudi Arabia
[2] King Saud Univ, Coll Med, Riyadh, Riyadh, Saudi Arabia
[3] Secur Forces Hosp Riyadh, Dept Otolaryngol Head & Neck Surg, Riyadh, Riyadh, Saudi Arabia
[4] Alsalamah Hosp, Dept Ophthalmol, Jeddah, Makkah, Saudi Arabia
[5] King Saud Bin Abdulaziz Univ Hlth Sci, Coll Med, Jeddah, Makkah, Saudi Arabia
关键词
5-Fluorouracil; scar management; facial plastic surgery; intralesional therapy; combination therapy; INTRALESIONAL; 5-FLUOROURACIL; MANAGEMENT; TRIAMCINOLONE; SCARS;
D O I
10.1055/a-2541-2644
中图分类号
R61 [外科手术学];
学科分类号
摘要
5-Fluorouracil (5-FU) is an antimetabolite that inhibits fibroblast proliferation and collagen synthesis, making it valuable in facial plastic surgery for scar modulation and other conditions. This systematic review examines the indications, outcomes, and safety of 5-FU in facial plastic surgery. Due to methodological heterogeneity across studies, a narrative synthesis was performed. A comprehensive search of MEDLINE, Cochrane, SCOPUS, EMBASE, PubMed, and Web of Science identified 32 eligible studies (1,456 patients) from 4,772 screened articles. Indications included keloids, hypertrophic scars, contractures, periocular scars, granulomas from filler complications, nasal skin thickening, infections following thread lifts, resistant facial warts, and hypochromic lesions. Most studies reported reductions in scar size, erythema, and recurrence rates, with combination therapies enhancing outcomes. Adverse effects were mild and transient. However, variability in dosing, administration frequency, and follow-up underscores the need for standardized treatment guidelines and long-term studies.
引用
收藏
页数:11
相关论文
共 38 条
[1]   Combination of Fractional Er:YAG Laser, Pulsed Dye Laser, and Intralesional Triamcinolone With 5-Fluorouracil for Keloid Treatment [J].
Anggawirya, Bonnie Yudistha ;
Wardhani, Putri Hendria ;
Indramaya, Diah Mira ;
Yulianto, Muhammad .
JOURNAL OF LASERS IN MEDICAL SCIENCES, 2023, 14
[2]  
Apikian Martine, 2004, Australas J Dermatol, V45, P140, DOI 10.1111/j.1440-0960.2004.00072.x
[3]   Is it possible to repigment iatrogenic and traumatic hypochromic lesions? A case series using the MMP® drug delivery technique with 5-fluorouracil and bleomycin [J].
Arbache, Samir ;
Arbache, Samia T. ;
Hirata, Sergio H. .
INTERNATIONAL JOURNAL OF DERMATOLOGY, 2022, 61 (01) :71-83
[4]   Combination therapy with 5-fluorouracil and salicylic acid in a treatment-resistant case of filiform facial warts [J].
Cartron, Alexander M. ;
Blaszczak, Alecia ;
Trinidad, John C. .
DERMATOLOGIC THERAPY, 2020, 33 (02)
[5]   Adverse granulomatous reaction to artecoll treated by intralesional 5-fluorouracil and triamcinolone injections [J].
Conejo-Mir, Julian S. ;
Guirado, Soledad Sanz ;
Munoz, Miguel Angel .
DERMATOLOGIC SURGERY, 2006, 32 (08) :1079-1082
[6]  
Erickson Taylor, 2018, Scars Burn Heal, V4, p2059513118818997, DOI 10.1177/2059513118818997
[7]   Treatment of inflamed hypertrophic scars using intralesional 5-FU [J].
Fitzpatrick, RE .
DERMATOLOGIC SURGERY, 1999, 25 (03) :224-232
[8]   Challenges in the Management of Upper Lid Keloid [J].
Goel, Ruchi ;
Khanam, Samreen ;
Shah, Shalin ;
Saran, Ravindra Kumar .
CASE REPORTS IN OPHTHALMOLOGICAL MEDICINE, 2022, 2022
[9]   Treatment of postdermabrasion facial hypertrophic and keloid scars with intralesional 5-fluorouracil injections [J].
Goldan, O. ;
Weissman, O. ;
Regev, E. ;
Haik, J. ;
Winkler, E. .
AESTHETIC PLASTIC SURGERY, 2008, 32 (02) :389-392
[10]   Use of 5-Fluorouracil Injections in Traumatic Cicatricial Malposition of Eyelids [J].
Gupta, Roshmi ;
Thomas, Rwituja ;
Almukhtar, Fatema ;
Kiran, Anjali .
PLASTIC AND RECONSTRUCTIVE SURGERY, 2022, 150 (03) :713E-+